RESUMEN
OBJECTIVE: Androgen deprivation therapy (ADT) remains a widely utilized modality for treatment of localized and advanced prostate cancer. While ADT-induced alterations in testosterone have demonstrated impacts on quality of life, the effects on mental health remain ill-defined. We investigated the prevalence of de novo psychiatric illness and predictive factors following ADT induction for prostate cancer. MATERIALS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between 1/1989-7/2005, excluding men receiving only neoadjuvant ADT. Variables included age, race, body mass index, prostate-specific antigen (PSA), Gleason sum, clinical stage, ADT type (medical/surgical) and schedule (continuous/intermittent), and presence of pre-ADT and newly diagnosed psychiatric illness. The cohort was divided into three groups for analysis: pre-ADT psychiatric illness, de novo psychiatric illness, and no psychiatric illness. Data analysis utilized statistical software with p < 0.05 considered significant. RESULTS: Three-hundred and ninety-five patients with a mean age of 71.7 years at ADT initiation were analyzed. Thirty-four men (8.6%) were diagnosed with pre-ADT psychiatric illness. At mean follow-up of 87.4 months, 101 (27.9%) men were diagnosed with de novo psychiatric illness, most commonly including: depression (n = 57; 56.4%), dementia (n = 14; 13.9%), and anxiety (n = 9; 8.9%). On multivariate analysis, increasing pre-ADT PSA was predictive of post-ADT anxiety (p = 0.01). Overall and disease-specific survival outcomes were similar between groups. CONCLUSIONS: De novo psychiatric illness was identified in 27.9% of men. While no predictive factors were identified for de novo psychiatric illness, increasing PSA was associated with de novo anxiety. Prospective investigation using validated instruments is requisite to further delineate the relationship between ADT and psychiatric health.
Asunto(s)
Antagonistas de Andrógenos/uso terapéutico , Ansiedad/epidemiología , Demencia/epidemiología , Depresión/epidemiología , Neoplasias de la Próstata/tratamiento farmacológico , Neoplasias de la Próstata/psicología , Anciano , Anciano de 80 o más Años , Antagonistas de Andrógenos/efectos adversos , Ansiedad/inducido químicamente , Ansiedad/fisiopatología , Demencia/inducido químicamente , Demencia/fisiopatología , Depresión/inducido químicamente , Depresión/fisiopatología , Humanos , Modelos Logísticos , Masculino , Salud Mental , Persona de Mediana Edad , Análisis Multivariante , Orquiectomía , Estudios RetrospectivosRESUMEN
OBJECTIVE: To investigate the incidence of patient-reported erectile (ED) and sexual dysfunction and response to treatment in men after the induction of androgen deprivation therapy (ADT) for prostate cancer, as ADT-induced changes in serum testosterone can result in changes in libido and sexual function. PATIENTS AND METHODS: We retrospectively reviewed patients receiving ADT for prostate cancer at our institution between January 1989 and July 2005; those receiving only neoadjuvant ADT were excluded. Variables included age, race, body mass index, prostate-specific antigen level before ADT, Gleason sum, clinical stage, ADT type (medical vs surgical) and schedule (continuous vs intermittent), previous treatment for prostate cancer, presence of pre-existing or new-onset diabetes mellitus (DM), and presence of ED before ADT. After ADT induction, charts were reviewed for reporting of ED, changes in libido, and initiation of ED therapy (medical or surgical). RESULTS: In all, 395 patients (mean age of 71.7 years; 59.0% African-American, 41.0% Caucasian/other, at initiation ADT) were analysed. At mean follow-up of 87.4 months, 57 (14.4%) patients reported ED; 40 of these (70%) reported new-onset ED, while 17 (30%) reported ED before ADT. Response rates were 33-80% with medical therapy, including 44% receiving phosphodiesterase-5 inhibitor monotherapy. On multivariate analysis, age <70 years (P < 0.001) and the absence of DM (P = 0.024) were associated with reporting ED after ADT. CONCLUSIONS: Patients receiving ADT for prostate cancer have variable degrees of ED. Successful outcomes are possible, particularly when implementing multimodal therapy. Younger patients and those with no DM are more likely to report ED after ADT induction.
Asunto(s)
Antagonistas de Andrógenos/efectos adversos , Antineoplásicos Hormonales/efectos adversos , Disfunción Eréctil/inducido químicamente , Libido/efectos de los fármacos , Inhibidores de Fosfodiesterasa/uso terapéutico , Neoplasias de la Próstata/tratamiento farmacológico , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Andrógenos/metabolismo , Disfunción Eréctil/tratamiento farmacológico , Humanos , Masculino , Persona de Mediana Edad , Erección Peniana/efectos de los fármacos , Análisis de Regresión , Estudios RetrospectivosRESUMEN
OBJECTIVES: Adrenal gland injury is a potentially devastating event if unrecognized in the treatment course of a trauma patient. We reviewed our single-center experience and outcomes in patients with adrenal gland trauma. METHODS: We performed a retrospective review of all patients presenting with trauma to the Regional Medical Center at Memphis who had adrenal gland injuries from January 1991 through March 2006. Each chart was reviewed with attention to the demographics, associated injuries, complications, and outcomes. Patients were stratified into two subgroups according to age (35 years or younger and older than 35 years) to allow for an age-based comparison between the two groups. RESULTS: Of 58,000 patients presenting with trauma, 130 (0.22%) were identified with adrenal injuries, of which 8 (6.2%) were isolated and 122 (93.8%) were not. Of these 130 patients, 125 (96.2%) had their injury diagnosed by computed tomography and 5 (3.8%) had their injury diagnosed during exploratory laparotomy. Right-sided injuries predominated (78.5%), with six (4.6%) bilateral. Four patients (3.1%) underwent adrenalectomy. Seven patients (5.4%) with adrenal injuries died. One patient (0.77%) required chronic steroid therapy. Patients older than 35 years were more likely to have complications such as deep venous thrombosis, pneumonia, and urinary tract infections. Patient age of 35 years or younger was associated with a significantly increased incidence of liver lacerations. CONCLUSIONS: Adrenal gland injury is uncommon, although mostly associated with greater injury severity. Although adding to morbidity, most are self-limited and do not require intervention.
Asunto(s)
Glándulas Suprarrenales/lesiones , Adolescente , Glándulas Suprarrenales/cirugía , Adrenalectomía , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Femenino , Humanos , Masculino , Persona de Mediana Edad , Traumatismo Múltiple/diagnóstico , Traumatismo Múltiple/terapia , Estudios Retrospectivos , Centros Traumatológicos , Heridas y Lesiones/diagnóstico , Heridas y Lesiones/terapiaRESUMEN
INTRODUCTION: Androgen deprivation therapy (ADT) is widely utilized for treatment of localized and advanced prostate cancer (CaP). ADT is associated with increased rates of osteoporosis; however, its impact on fracture risk is not completely understood. We investigated incidence and predisposing factors for osteoporosis and fractures in a large, contemporary, single institution series of patients treated with ADT for CaP. METHODS: We retrospectively reviewed medical records of all patients who received ADT for CaP between 1/1989 and 7/2005. Primary endpoints of investigation were osteoporosis and non-pathologic fractures. Independent variables included age, race, body mass index (BMI), pretreatment serum PSA, Gleason sum, clinical stage, ADT type (medical versus surgical) and schedule (continuous versus intermittent), and receipt of calcium, vitamin D or bisphosphonate supplementation. Data were analyzed by Chi-square test, Student's t-test, Linear Regression, and Logistic Regression (p < 0.05 significant). RESULTS: A total of 395 patients were analyzed (mean age 71.7 years, 59% African American, 41% Caucasian/other). At mean follow-up of 66.1 months, 92 (23%) patients developed osteoporosis and 27 (7%) patients developed non-pathologic fractures. On univariate analysis, age, race, BMI, and ADT duration were significantly associated with osteoporosis development, while BMI, ADT duration, and presence of osteoporosis were significantly associated with fracture incidence. Regression analysis revealed that age > 70 at ADT initiation, continuous ADT, and increased treatment duration predicted osteoporosis development, while only osteoporosis was independently predictive of fracture development. CONCLUSIONS: Patients receiving continuous ADT for CaP are at increased risk for developing osteoporosis which may lead to fractures, with an incidence of 7% in our study population.